Literature DB >> 24758631

Romosozumab in postmenopausal women with osteopenia.

Pieter Evenepoel, Patrick D'Haese, Vincent Brandenburg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24758631     DOI： 10.1056/NEJMc1402396

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  12 in total

Review 1.  LRP receptor family member associated bone disease.

Authors:  N Lara-Castillo; M L Johnson
Journal:  Rev Endocr Metab Disord       Date:  2015-06       Impact factor: 6.514

Review 2.  Side effects of drugs for osteoporosis and metastatic bone disease.

Authors:  Michael Kriegbaum Skjødt; Morten Frost; Bo Abrahamsen
Journal:  Br J Clin Pharmacol       Date:  2018-10-17       Impact factor: 4.335

Review 3.  From skeletal to cardiovascular disease in 12 steps-the evolution of sclerostin as a major player in CKD-MBD.

Authors:  Vincent M Brandenburg; Patrick D'Haese; Annika Deck; Djalila Mekahli; Björn Meijers; Ellen Neven; Pieter Evenepoel
Journal:  Pediatr Nephrol       Date:  2015-03-04       Impact factor: 3.714

Review 4.  Perspectives on osteoporosis therapies.

Authors:  E Cairoli; V V Zhukouskaya; C Eller-Vainicher; I Chiodini
Journal:  J Endocrinol Invest       Date:  2015-01-11       Impact factor: 4.256

5.  Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification.

Authors:  Abdul Rashid Qureshi; Hannes Olauson; Anna Witasp; Mathias Haarhaus; Vincent Brandenburg; Annika Wernerson; Bengt Lindholm; Magnus Söderberg; Lars Wennberg; Louise Nordfors; Jonaz Ripsweden; Peter Barany; Peter Stenvinkel
Journal:  Kidney Int       Date:  2015-09-02       Impact factor: 10.612

6.  Evaluating the cardiovascular safety of sclerostin inhibition using evidence from meta-analysis of clinical trials and human genetics.

Authors:  Jonas Bovijn; Kristi Krebs; Chia-Yen Chen; Ruth Boxall; Jenny C Censin; Teresa Ferreira; Sara L Pulit; Craig A Glastonbury; Samantha Laber; Iona Y Millwood; Kuang Lin; Liming Li; Zhengming Chen; Lili Milani; George Davey Smith; Robin G Walters; Reedik Mägi; Benjamin M Neale; Cecilia M Lindgren; Michael V Holmes
Journal:  Sci Transl Med       Date:  2020-06-24       Impact factor: 17.956

7.  Promoting effect of 1,25(OH)2 vitamin D3 in osteogenic differentiation from induced pluripotent stem cells to osteocyte-like cells.

Authors:  Hiroshi Kato; Hiromi Ochiai-Shino; Shoko Onodera; Akiko Saito; Takahiko Shibahara; Toshifumi Azuma
Journal:  Open Biol       Date:  2015-02       Impact factor: 6.411

8.  Efficacy of Intraperitoneal Administration of PEGylated NELL-1 for Bone Formation.

Authors:  Justine Tanjaya; Yulong Zhang; Soonchul Lee; Jiayu Shi; Eric Chen; Pia Ang; Xinli Zhang; Sotirios Tetradis; Kang Ting; Benjamin Wu; Chia Soo; Jin Hee Kwak
Journal:  Biores Open Access       Date:  2016-06-01

Review 9.  Treatment of Osteoporosis, with a Focus on 2 Monoclonal Antibodies.

Authors:  Biao Chang; Qi Quan; Yunqi Li; Haixia Qiu; Jiang Peng; Ying Gu
Journal:  Med Sci Monit       Date:  2018-12-03

10.  Ciliotherapy Treatments to Enhance Biochemically- and Biophysically-Induced Mesenchymal Stem Cell Osteogenesis: A Comparison Study.

Authors:  M A Corrigan; T M Ferradaes; M Riffault; D A Hoey
Journal:  Cell Mol Bioeng       Date:  2018-11-20       Impact factor: 2.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.